Medical device firm Focal Therapeutics is highlighting two studies that suggest the company's BioZorb surgical tissue marker improves treatment of women with breast cancer.
The first study was conducted by a team led by Dr. Michael Cross of Breast Treatment Associates in Fayetteville, AR. It was published in the World Journal of Surgery and describes how BioZorb provides more accurate targeting of the cancer tumor bed for radiation treatment when implanted during surgery.
Cross and colleagues included 108 patients with early-stage breast cancer who received the marker during a procedure called reconstructive lumpectomy. None of the patients experienced device-related complications or cancer recurrence (World J Surg, October 5, 2016).
Results of the second study were presented at the recent American Society for Radiation Oncology (ASTRO) meeting in Boston. Dr. William Hall of St. Joseph Medical Center in Bellingham, WA, and Dr. Cary Kaufman of Bellingham Regional Breast Center found that BioZorb reduced the amount of normal breast and surrounding tissue that were exposed to radiation treatment on average by 65%, the company said.
